Evidence map›Paper›PMID 26105515›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2016

KPS/LDH index: a simple tool for identifying patients with metastatic melanoma who are unlikely to benefit from palliative whole brain radiotherapy.

Richard Partl, Gerd Fastner, Julia Kaiser, Elisabeth Kronhuber, Klaudia Cetin-Strohmer, Claudia Steffal, Barbara Böhmer-Breitfelder, Johannes Mayer, Alexander Avian, Andrea Berghold

Abstract read
PubMed Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Richard PartlDepartment of Therapeutic Radiology and Oncology, Medical University Graz, Comprehensive Cancer Center Graz, Auenbruggerplatz 32, 8036, Graz, Austria. richard.partl@medunigraz.at.
Gerd FastnerDepartment of Radiotherapy and Radio-Oncology, Landeskrankenhaus Salzburg, Paracelsus Medical University, Salzburg, 5020, Austria.
Julia KaiserDepartment of Radiotherapy and Radio-Oncology, Landeskrankenhaus Salzburg, Paracelsus Medical University, Salzburg, 5020, Austria.
Elisabeth KronhuberInstitute of Radiooncology, General Hospital, Wr. Neustadt, Vienna, 2700, Austria.
Klaudia Cetin-StrohmerInstitute of Radiooncology, General Hospital, Wr. Neustadt, Vienna, 2700, Austria.
Claudia SteffalInstitute of Radiooncology, Kaiser-Franz-Josef-Spital, Vienna, 1100, Austria.
Barbara Böhmer-BreitfelderDepartment of Radiooncology, Krems Hospital, Vienna, 3530, Austria.
Johannes MayerDepartment of Radiooncology, Krems Hospital, Vienna, 3530, Austria.
Alexander AvianInstitute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Comprehensive Cancer Center Graz, Graz, 8036, Austria.
Andrea BergholdInstitute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Comprehensive Cancer Center Graz, Graz, 8036, Austria.
Medical University of Graz · ATParacelsus Medical University · ATUniversitätsklinikum Krems · ATVienna General Hospital · ATKaiser-Franz-Josef-Spital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeLow Karnofsky performance status (KPS) and elevated lactate dehydrogenases (LDHs) as a surrogate marker for tumor load and cell turnover may depict patients with a very short life expectancy. To validate this finding and compare it to other indices, namely, the recursive partitioning analysis (RPA) and diagnosis-specific graded prognostic assessment (DS-GPA), a multicenter analysis was undertaken.

methodsA retrospective analysis of 234 metastatic melanoma patients uniformly treated with palliative whole brain radiotherapy (WBRT) was done. Univariate and multivariate analyses were used to determine the impact of patient-, tumor-, and treatment-related parameters on overall survival (OS).

resultsKPS and LDH emerged as independent factors predicting OS. By combining KPS and LDH values (KPS/LDH index), groups of patients with statistically significant differences in median OS (days; 95 % CI) after onset of WBRT were identified: group 1 (KPS ≥ 70/normal LDH) 234 (96-372), group 2 (KPS ≥ 70/elevated LDH) 112 (69-155), group 3 (KPS <70/normal LDH) 43 (12-74), and group 4 (KPS <70/elevated LDH) 29 (17-41). Between all four groups, statistically significant differences were observed. The RPA and DS-GPA indices failed to distinguish significantly between good and moderate prognosis and were inferior in predicting a very unfavorable prognosis.

conclusionsThe parameters KPS and LDH independently impacted on OS. The combination of both (KPS/LDH index) identified patients with a very short life expectancy, who might be better served by recommending best supportive care instead of WBRT. The KPS/LDH index is simple and effective in terms of time and cost as compared to other prognostic indices.

Indexed as

Karnofsky Performance StatusAdultAgedAged, 80 and overBiomarkers, TumorBrainBrain NeoplasmsFemaleHumansLactate DehydrogenasesMaleMelanomaMiddle AgedMultivariate AnalysisPrognosisRetrospective StudiesBiomarkers, TumorLactate DehydrogenasesBrain metastasisLDHMelanomaPrognostic scoreWBRT

Identifiers

PMID26105515
OpenAlexW850030597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.